Horesh Nurit, Weiler-Sagie Michal, Ringelstein-Harlev Shimrit
Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus Haifa, Israel.
Department of Nuclear Medicine, Rambam Health Care Campus Haifa, Israel.
Am J Blood Res. 2021 Feb 15;11(1):111-117. eCollection 2021.
Relapsed/refractory diffuse large B-cell lymphoma (DLBCL) portends a poor prognosis, with an estimated overall survival of less than 6 months. In the presented case, a female patient with DLBCL refractory to multiple lines of therapy, including chimeric antigen receptor T-cells, was treated with single-agent selinexor, achieving partial response following 5 months of treatment, which allowed the patient to proceed to potentially curative allogeneic stem cell transplantion. This approach enabled the patient, who would otherwise have been considered a candidate for palliative care, to achieve the most prolonged complete response since her first lymphoma-specific treatment. This outcome implies that early identification of relapsed/refractory patients who may benefit most from this drug - either as a single agent or in drug combinations - is imperative.
复发/难治性弥漫性大B细胞淋巴瘤（DLBCL）预后不良，估计总生存期不到6个月。在本病例中，一名患有DLBCL的女性患者对包括嵌合抗原受体T细胞在内的多线治疗均耐药，接受了单药塞利尼索治疗，治疗5个月后获得部分缓解，这使患者能够进行可能治愈性的异基因干细胞移植。这种方法使该患者（否则将被视为姑息治疗的候选者）自首次淋巴瘤特异性治疗以来实现了最长时间的完全缓解。这一结果表明，必须尽早识别出可能从这种药物（无论是单药还是联合用药）中获益最大的复发/难治性患者。
